Regulatory reforms impact drug approvals by making the process more efficient and flexible. For instance, the FDA's Oncology Center of Excellence has implemented initiatives like the Real-Time Oncology Review (RTOR) pilot program, which allows for earlier submission and review of trial data. This has led to faster approvals of effective cancer treatments. Additionally, reforms that support the use of surrogate endpoints can expedite the approval of drugs that show promise in early stages of clinical trials.
